Examkin

Question

Difficulty: MediumPediatric Hematology and Oncology

A 99-year-old boy is diagnosed with Burkitt lymphoma after presenting with a rapidly enlarging abdominal mass and abdominal pain. Laboratory studies reveal a white blood cell count of 14,000/mm314,000/\text{mm}^3, a uric acid level of 11.2 mg/dL11.2 \text{ mg/dL}, potassium of 5.1 mEq/L5.1 \text{ mEq/L}, phosphorus of 6.5 mg/dL6.5 \text{ mg/dL}, and calcium of 7.2 mg/dL7.2 \text{ mg/dL}. His serum creatinine is 0.8 mg/dL0.8 \text{ mg/dL}. He is admitted to the pediatric intensive care unit for management. Arrange the following steps in the most appropriate chronological order for the prevention and management of tumor lysis syndrome (TLS) and its potential complications in this patient, starting from the initial intervention upon admission.

  1. 1Initiation of aggressive intravenous fluid hydration without potassium
  2. 2Administration of rasburicase (recombinant urate oxidase)
  3. 3Initiation of systemic cytotoxic chemotherapy
  4. 4Initiation of renal replacement therapy (e.g., hemodialysis)

Answer

The correct sequence is: (1) Initiation of aggressive intravenous fluid hydration without potassium, (2) Administration of rasburicase, (3) Initiation of systemic cytotoxic chemotherapy, and (4) Initiation of renal replacement therapy.
In a patient with a highly proliferative malignancy such as Burkitt lymphoma and established laboratory tumor lysis syndrome (TLS), the immediate priority is protecting renal function. Aggressive intravenous hydration without potassium is the critical first step to promote diuresis and prevent crystal precipitation. This is closely followed by rasburicase, which rapidly degrades existing uric acid into the highly soluble compound allantoin. Once prophylactic measures have mitigated the risk of catastrophic cell breakdown, systemic cytotoxic chemotherapy can be safely initiated to treat the underlying malignancy. Finally, if the patient develops refractory oliguria, volume overload, or intractable hyperkalemia despite optimal medical management, renal replacement therapy (hemodialysis) serves as a last-resort rescue intervention.

Step-by-Step Solution

1
Identify the clinical scenario
The patient has a highly proliferative malignancy (Burkitt lymphoma) and presents with laboratory evidence of spontaneous tumor lysis syndrome (TLS) prior to chemotherapy.
Understanding the patient's risk profile dictates the urgency and aggressiveness of medical prophylaxis.
2
Determine the first priority in management
Aggressive intravenous hydration is selected as the initial intervention.
Hyperhydration improves renal perfusion and increases urine output, which is critical for flushing uric acid and phosphate crystals from the renal tubules.
3
Select the appropriate pharmacologic intervention
Rasburicase is administered to rapidly lower uric acid levels.
Given the already elevated uric acid (11.2 mg/dL11.2 \text{ mg/dL}), rasburicase is indicated over allopurinol because it enzymatically degrades existing uric acid into highly soluble allantoin.
4
Determine the timing of tumor-directed therapy
Systemic cytotoxic chemotherapy is initiated only after TLS prophylaxis is established.
Chemotherapy will cause rapid tumor cell lysis; if given before prophylaxis, it would precipitate catastrophic metabolic derangements and acute renal failure.
5
Identify the indication for rescue therapy
Renal replacement therapy is positioned as the final, conditional step.
Hemodialysis is reserved for severe cases where medical management fails to prevent oliguric acute kidney injury, severe hyperkalemia, or volume overload.

Key Concept

The chronological management of tumor lysis syndrome prioritizes aggressive intravenous hydration and hypouricemic agents before initiating cytotoxic chemotherapy, with renal replacement therapy reserved for refractory acute kidney injury.
Rate this question

Topics

Pediatric Hematology and Oncology

More questions from this topic